MedTrace Logo

A Study of CM310 in Children Patients With Moderate-to-severe Atopic Dermatis

NCT05579925 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2024-11-08

No results posted yet for this study

Summary

This is a multi-center, single arm, open-label study to evaluate safety and primary efficacy in children patients with moderate-to severe atopic dermatis.

Conditions

Interventions

BIOLOGICAL

CM310

CM310 600 mg + 300 mg, subcutaneous injection

Sponsors & Collaborators

  • Keymed Biosciences Co.Ltd

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-07
Primary Completion
2023-07-28
Completion
2023-07-28

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05579925 on ClinicalTrials.gov